Refine Search

Search Results -

Terms	Documents
L2 and (dry adj powder)	20

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L9

Refine Search

Recall Text Clear Interrupt

Search History

DATE: Wednesday, May 10, 2006 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L9	L2 and (dry adj powder)	20	L9
DB=PGPB,USPT; PLUR=YES; OP=OR			
L8	Joseph near Sulner	4	L8
L7	Rodney near Woods	26	L7
L6	solomon near Steiner	29	L6
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L5	solomon near Steiner	42	L5
L4	L3 and (dry adj powder)	13	L4
L3	L2 and diabetes	115	L3
L2	L1 and diketopiperazine	172	L2
L1	insulin	76876	L1

END OF SEARCH HISTORY

PALM INTRANET

Day : Wednesday

Date: 5/10/2006
Time: 23:00:15

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	**First Name**	
Woods	Rodney	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

PALM INTRANET

Day : Wednesday

Date: 5/10/2006
Time: 23:00:15

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
Sulner	Joseph	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

PALM INTRANET

Day : Wednesday

Date: 5/10/2006
Time: 23:00:15

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	**First Name**	
Steiner	Solomon	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

(FILE 'HOME' ENTERED AT 21:01:16 ON 10 MAY 2006)

FILE 'CAPLUS, MEDLINE' ENTERED AT 21:01:25 ON 10 MAY 2006

L1 395176 S INSULIN
L2 38 S L1 AND DIKETOPIPERAZINE
L3 2 S L2 AND (DIKETOPIPERAZINE (10A) (FUMARYL OR SUCCINYL OR MALELY
L4 2 DUPLICATE REMOVE L3 (0 DUPLICATES REMOVED)
L5 31 DUPLICATE REMOVE L2 (7 DUPLICATES REMOVED)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
TI **Diketopiperazine** salts for drug delivery and related methods
AB Biol. active agent delivery compns., which comprise **diketopiperazine** carboxylate salts are provided. Related methods for making and using the biol. active agent delivery compns. are also provided. For example, microparticles containing disodium **fumaryl diketopiperazine** and **insulin** was fabricated through spray drying and used to deliver **insulin**.

ACCESSION NUMBER: 2006:170457 CAPLUS
DOCUMENT NUMBER: 144:260796
TITLE: **Diketopiperazine** salts for drug delivery and related methods
INVENTOR(S): Leone-Bay, Andrea; Moye-Sherman, Destardi; Wilson, Bryan R.
PATENT ASSIGNEE(S): Mannkind Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 24 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006040953	A1	20060223	US 2005-210710	20050823
WO 2006023943	A1	20060302	WO 2005-US30026	20050823

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-603761P P 20040823
OTHER SOURCE(S): MARPAT 144:260796

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
TI Purification and stabilization of peptide and protein pharmaceutical agents
AB Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a **diketopiperazine** or competitive complexing agent to facilitate removal of one or more impurities, i.e. undesirable components, from the peptide or protein. In a preferred embodiment, a peptide, such as **insulin**, containing one or more impurities, e.g. zinc ions, is entrapped in **diketopiperazine** to form a precipitate of peptide/**diketopiperazine**/impurity, which is then washed with a solvent for the impurity to be removed, which is a nonsolvent for the **diketopiperazine** and a nonsolvent for the peptide. Formulations and methods also are provided for the improved transport of active agents across biol. membranes, resulting for example in a rapid increase in blood agent concentration The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biol. membrane in order to facilitate transport. In a preferred embodiment, **insulin** is administered via the pulmonary delivery of microparticles comprising **fumaryl diketopiperazine** and **insulin** in its biol. active form. The charge on the **insulin** mol. is masked by

hydrogen bonding it to the **diketopiperazine**, thereby enabling the **insulin** to pass through the target membrane. This method of delivering **insulin** results in a rapid increase in blood **insulin** concentration that is comparable to the increase resulting from i.v. delivery.

ACCESSION NUMBER: 2001:12479 CAPLUS
DOCUMENT NUMBER: 134:76414
TITLE: Purification and stabilization of peptide and protein pharmaceutical agents
INVENTOR(S): Steiner, Solomon S.; Woods, Rodney J.; Sulner, Joseph W.
PATENT ASSIGNEE(S): Pharmaceutical Discovery Corporation, USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000654	A2	20010104	WO 2000-US17984	20000629
WO 2001000654	A3	20010705		
WO 2001000654	C2	20020725		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2377204	AA	20010104	CA 2000-2377204	20000629
EP 1196430	A2	20020417	EP 2000-945009	20000629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6444226	B1	20020903	US 2000-606468	20000629
JP 2003503420	T2	20030128	JP 2001-507061	20000629
AU 779986	B2	20050224	AU 2000-59010	20000629
US 2003013641	A1	20030116	US 2002-224761	20020820
US 6652885	B2	20031125		
US 2004077528	A1	20040422	US 2003-719734	20031121
AU 2005202230	A1	20050616	AU 2005-202230	20050523

PRIORITY APPLN. INFO.:

US 1999-141433P	P	19990629
US 2000-606468	A3	20000629
WO 2000-US17984	W	20000629
US 2002-224761	A1	20020820

L5 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
TI **Diketopiperazine** salts for drug delivery and related methods
AB Biol. active agent delivery compns., which comprise **diketopiperazine** carboxylate salts are provided. Related methods for making and using the biol. active agent delivery compns. are also provided. For example, microparticles containing disodium fumaryl **diketopiperazine** and **insulin** was fabricated through spray drying and used to deliver **insulin**.

ACCESSION NUMBER: 2006:170457 CAPLUS
DOCUMENT NUMBER: 144:260796
TITLE: **Diketopiperazine** salts for drug delivery and related methods
INVENTOR(S): Leone-Bay, Andrea; Moye-Sherman, Destardi; Wilson, Bryan R.
PATENT ASSIGNEE(S): Mannkind Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 24 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006040953	A1	20060223	US 2005-210710	20050823
WO 2006023943	A1	20060302	WO 2005-US30026	20050823

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-603761P P 20040823
OTHER SOURCE(S): MARPAT 144:260796

L5 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method of reducing serum proinsulin levels in type 2 diabetics
AB Methods are provided for reducing serum proinsulin levels, lessening post-prandial pancreatic stress, and reducing risk factors for atherosclerosis in subjects with diabetes mellitus, type 2. The method includes administration of **insulin** in a manner that mimics the meal-related first phase **insulin** response, using a dose sufficient to reduce serum levels of proinsulin. In some embodiments of the method **insulin** administration is commenced early in the course of the disease. Mimicking first phase kinetics, peak serum **insulin** levels can be reached within about 18 min of administration. In increasingly preferred embodiments peak serum **insulin** levels can be reached within about 15, 12, or 10 min of administration. Serum **insulin** levels return to baseline within about two hours of administration. The invention relates to administration of **insulin** by pulmonary delivery using synthetic biodegradable polymeric or **diketopiperazine** microparticles incorporating the **insulin**.

ACCESSION NUMBER: 2005:614581 CAPLUS
DOCUMENT NUMBER: 143:71798
TITLE: Method of reducing serum proinsulin levels in type 2 diabetics

INVENTOR(S): Cheatham, Wayman Wendell; Boss, Anders Hasager; Pfuetzner, Andreas
PATENT ASSIGNEE(S): Mannkind Corp., USA
SOURCE: U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005153874	A1	20050714	US 2005-32278	20050110
WO 2005067964	A1	20050728	WO 2005-US596	20050110

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-535945P P 20040112

L5 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
TI Purification and stabilization of peptide and protein pharmaceutical agents
AB Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a **diketopiperazine** or competitive complexing agent to facilitate removal of one or more impurities, i.e. undesirable components, from the peptide or protein. In a preferred embodiment, a peptide, such as **insulin**, containing one or more impurities, e.g. zinc ions, is entrapped in **diketopiperazine** to form a precipitate of peptide/**diketopiperazine**/impurity, which is then washed with a solvent for the impurity to be removed, which is a nonsolvent for the **diketopiperazine** and a nonsolvent for the peptide. Formulations and methods also are provided for the improved transport of active agents across biol. membranes, resulting for example in a rapid increase in blood agent concentration The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biol. membrane in order to facilitate transport. In a preferred embodiment, **insulin** is administered via the pulmonary delivery of microparticles comprising fumaryl **diketopiperazine** and **insulin** in its biol. active form. The charge on the **insulin** mol. is masked by hydrogen bonding it to the **diketopiperazine**, thereby enabling the **insulin** to pass through the target membrane. This method of delivering **insulin** results in a rapid increase in blood **insulin** concentration that is comparable to the increase resulting from i.v. delivery.
ACCESSION NUMBER: 2001:12479 CAPLUS
DOCUMENT NUMBER: 134:76414
TITLE: Purification and stabilization of peptide and protein pharmaceutical agents
INVENTOR(S): Steiner, Solomon S.; Woods, Rodney J.; Sulner, Joseph W.
PATENT ASSIGNEE(S): Pharmaceutical Discovery Corporation, USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000654	A2	20010104	WO 2000-US17984	20000629
WO 2001000654	A3	20010705		
WO 2001000654	C2	20020725		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2377204	AA	20010104	CA 2000-2377204	20000629
EP 1196430	A2	20020417	EP 2000-945009	20000629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6444226	B1	20020903	US 2000-606468	20000629
JP 2003503420	T2	20030128	JP 2001-507061	20000629
AU 779986	B2	20050224	AU 2000-59010	20000629
US 2003013641	A1	20030116	US 2002-224761	20020820
US 6652885	B2	20031125		
US 2004077528	A1	20040422	US 2003-719734	20031121
AU 2005202230	A1	20050616	AU 2005-202230	20050523

PRIORITY APPLN. INFO.:

US 1999-141433P	P	19990629
US 2000-606468	A3	20000629
WO 2000-US17984	W	20000629
US 2002-224761	A1	20020820

L5 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method for making self-assembling **diketopiperazine** drug delivery system
AB Drug delivery systems are developed based on the formation of **diketopiperazine** (or analogs) microparticles. In the preferred embodiment, the microparticle is stable at low pH, disintegrates at physiol. pH, and is particularly useful for oral drug delivery. In other embodiments, the microparticles are stable at high pH and disintegrate at neutral or basic pH, or are stable at neutral pH and disintegrate at high or low pH. In the most preferred embodiment the microparticles are formed in the presence of the drug to be delivered, for example, **insulin**, felbamate, calcitonin, or heparin. The **diketopiperazine** synthetic intermediates are preferably formed by cyclodimerization to form **diketopiperazine** derivs. at elevated temps. under dehydrating conditions, functionalized on the side chains, and then precipitated with drugs to be incorporated into microparticles. Felbamate was encapsulated in 2,5-diketo-3,6-di(4-fumarylaminobutyl)piperazine (I) by adding 1.6 g of jet-milled, micronized felbamate to 320 mL of a 0.5% solution of Na lauryl sulfate in 0.1 M $NaHCO_3$ solution and then adding 4 g of I to the suspension.
ACCESSION NUMBER: 1996:256816 CAPLUS
DOCUMENT NUMBER: 124:352756
TITLE: Method for making self-assembling **diketopiperazine** drug delivery system
INVENTOR(S): Steiner, Solomon S.; Rhodes, Christopher A.; Shen, Gregory S.; Mccabe, R. Tyler
PATENT ASSIGNEE(S): Pharmaceutical Discovery Corporation, USA
SOURCE: U.S., 20 pp., Cont.-in-part of U.S. 5,352,461.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5503852	A	19960402	US 1994-299842	19940901
US 5352461	A	19941004	US 1992-849186	19920311
AT 132744	E	19960115	AT 1993-920574	19930311
ES 2089844	T3	19961001	ES 1993-920574	19930311

PRIORITY APPLN. INFO.: US 1992-849186 A2 19920311
OTHER SOURCE(S): MARPAT 124:352756

L5 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
TI Self-assembling **diketopiperazine** drug delivery system
AB Drug delivery systems based on the formation of **diketopiperazine** or analog microparticles are developed. The microparticles are stable at low pH and are disintegrated at physiol. pH. Thus, 2,5-diketo-3,6-di(4-aminobutyl)piperazine (preparation is given) was succinylated with succinic anhydride in alkaline solution to obtain 2,5-diketo-3,6-di(4-succinylaminobutyl)piperazine (I) which was rapidly acidified with citric acid at pH=2.2 to sep. I as microparticles. Porcine **insulin** (II) was encapsulated in I by dissolving I in a saturated NaHCO3 solution and mixing this solution with an equal volume of 1M citric acid soln containing II at a concentration of 20mgII/mL. Rats were given 1mL oral encapsulated II suspension at a concentration of 10mg/kg of body weight Encapsulated I produced a marked fall in blood glucose level as compared with amorphous precipitate solution of I and II which failed to do so.
ACCESSION NUMBER: 1993:656544 CAPLUS
DOCUMENT NUMBER: 119:256544
TITLE: Self-assembling **diketopiperazine** drug delivery system
INVENTOR(S): Feldstein, Robert; Glass, John; Steiner, Solomon S.
PATENT ASSIGNEE(S): Pharmaceutical Discovery Corp., USA
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9318754	A1	19930930	WO 1993-US2245	19930311
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5352461	A	19941004	US 1992-849186	19920311
AU 9338044	A1	19931021	AU 1993-38044	19930311
AU 680408	B2	19970731		
EP 630236	A1	19941228	EP 1993-920574	19930311
EP 630236	B1	19960110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07506818	T2	19950727	JP 1993-516624	19930311
AT 132744	E	19960115	AT 1993-920574	19930311
ES 2089844	T3	19961001	ES 1993-920574	19930311
CA 2131366	C	20030923	CA 1993-2131366	19930311

PRIORITY APPLN. INFO.: US 1992-849186 A 19920311
WO 1993-US2245 A 19930311
OTHER SOURCE(S): MARPAT 119:256544